05/17/2019
Ogier advises on US$350 million biopharmaceutical merger
The merger transaction was essentially an all share deal, with Xynomic's shareholders receiving shares in Bison equivalent to a closing consideration value of approximately US$ 350 million subject to certain adjustments for debt, cash and working cap